Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Completed 4Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Glioblastoma 11Glioma 4Sarcoma, Ewing 2Recurrence 2Medulloblastoma 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Sarcoma 1SCLC, Extensive Stage 1Rhabdomyosarcoma 1Primary Glioblastoma 1Pancreatic Neoplasms 1Osteosarcoma 1Melanoma 1Lymphoma, Follicular 1Hypoxia 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Astrocytoma 1Advanced Glioblastoma 1

Interventions

surufatinib 1irinotecan sucrosofate 1envafolimab 1anlotinib 1Vincristine 1Temozolomide 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Neoadjuvant Therapy 1Methotrexate 1Ifosfamide 1Etoposide 1Epirubicin 1Drug Therapy 1Brachytherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Osteosarcoma × Temozolomide × Clear all
NCT07444918 2026-03-03

Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
33 enrolled
Sarcoma

Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡